NOTICIASCIENTÍFICAS…
249
8. Lin, T. I; Lenz, O; Fanning, G; Verbinnen, T; Delouvroy, F; Scholliers, A; Vermeiren, K;
Rosenquist, A; Edlund, M; Samuelsson, B.; Vrang, L.; DeKock, H.;Wigerinck, P.; Raboisson,
P.; Simmen, K. (2009) "In vitro activity and preclinical profile of TMC435350, a potent
hepatitisCvirusprotease inhibitor"
Antimicrob. Agents andChemother.,
53, 1377-‐1385.
9. Gao, M.; Nettles, R. E.; Belema, M.; Zinder, L. B.; Nguyen, V. N.; Fridell, R. A.; Serrano-‐Wu, M.
H.; Langley, D. R.; Sun, J. H.; O'Boyle, D. R.; Lemm, J. A.; Wang, C.; Knipe, J. O.; Chien, C.;
Colonno, R. J.; Grasela, D. M.; Meanwell, N. A.; Hamann, L. G. (2010) “Chemical genetics
strategy identifies an HCV NS5A inhibitor with a potent clinical effect”
Nature
, 465, 96-‐
100.
10. Lok, A. S.; Gardiner, D. F.; Lawitz, E.; Martorell, C.; Everson, G. T.; Ghalib, R.; Reindollar, R.;
Rustgi, V.; McPhee, F.;Wind-‐Rotolo, M.; Persson, A.; Zhu, K.; Dimitrova, D. I.; Eley, T.; Guo,
T.; Grasela, D. N.; Pasquinelli, C.; (2012) “Preliminary Study of Two Antiviral Agents for
HepatitisCGenotype1”,
NewEngl. J.Med
. 366, 216-‐224.
11. Lupberger
, J.;
Zeisel
,M. B.;
Xiao
, F.;
Thumann
, Ch.;
Fofana
, I.;
Zona
, L.;
Davis
, Ch.;
Mee
, Ch. J.;
Turek
,M.;
Gorke
, S.;
Royer
, C.;
Fischer
, B.;
Zahid
,M. N.;
Lavillette
, D.;
Fresquet
, J.;
Cosset
, F.-‐
L.;
Rothenberg
, S. M.;
Pietschmann
, T.;
Patel
, A. H.;
Pessaux
, P.;
Doffoël
, M.;
Raffelsberger
,
W.;
Poch
, O.;
McKeating
, J. A.;
Brino, L.;
et al.
(2011) “EGFR andEphA2 are host factors for
hepatitisCvirus entryandpossible targets for antiviral therapy”
NatureMedicine
, 17, 589-‐
595.
12. Sulkowski, M. S.; Kang, M.;Matining, R.;Wyles, D.; Johnson, V. A.;Morse, G. D.; Amorosa, V.;
Bhattacharya, D.; Coughlin, K.; Wong-‐Staal, F.; Glesby, M. J.; (2014) “Safety and Antiviral
Activity of the HCV Entry Inhibitor ITX5061 in Treatment-‐Naive HCV-‐Infected Adults: A
Randomized, Double-‐Blind, Phase1bStudy”,
J. Infect. Dis.
209, 658-‐667.
13. Ferenci, P.; Bernstein, D.; Lalezari, J.; Cohen, D.; Luo, Y.; Cooper, C.; Tam, E.; Marinho, R. T.;
Tsai, N.; Nyberg, A.; Box, T. D.; Younes, Z.; Enayati, P.; Green, S.; Baruch, Y.; Bhandari, B. R.;
Caruntu, F. A.; Sepe, T.; Chulanov, V.; Janczewska, E.; Rizzardini, G.; Gervain, J.; Planas,
Planas; Moreno, Ch.; Hassanein, T.; Xie, W.; King, M.; Podsadecki, T.; Reddy, K. R.; (2014)
“ABT-‐450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV”,
New Eng. J.
Med.
DOI: 10.1056/NEJMoa1402338.
